Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Kennedy and Milei double down on WHO exit...
Trump claims Canada ‘considering’ offer of free Golden...
‘Intensely loyal’ Jill Biden aide despised by White...
Defense Department workers no longer required to submit...
SEN. RAND PAUL: Kennedy is confronting ‘corrupt’ health...
DeSantis goads Congress to follow FL’s DOGE blueprint...
Trump order targeting law firm WilmerHale blocked as...
US military vulnerabilities threaten Trump’s ‘peace-through-strength’ strategy
Succeeding Trump: 6 Republican potential presidential hopefuls to...
Watchdog finds ‘no evidence’ Biden knew of crucial...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

5 Small-cap Biotech ETFs to Watch (Updated 2024)

by admin August 17, 2024
August 17, 2024
5 Small-cap Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.

ETFs are a popular choice as they allow investors to enter the market more safely compared to investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

All other figures were also current as of that date. Read on to learn more about these investment vehicles.

1. ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB)

Company Profile

AUM: US$87.99 million

The ProShares Ultra NASDAQ Biotechnology ETF was launched in April 2010 and is leveraged to offer twice daily long exposure to the broad-based NASDAQ Biotechnology Index, making it an ideal choice “for investors with a bullish short-term outlook for biotechnology or pharmaceutical companies.” However, analysts also advise investors with a low risk tolerance or a buy-and-hold strategy against investing in this fund due to its unique nature.

Of the 218 holdings in this ETF, the top biotech stocks in the ETF are Regeneron Pharmaceuticals (NASDAQ:REGN) at a 6.01 percent, Gilead Sciences (NASDAQ:GILD) at 5.97 percent and Amgen (NASDAQ:AMGN) at 5.49 percent.

2. Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Company Profile

AUM: US$82.83 million

The Global X Genomics & Biotechnology ETF tracks genomic science stocks, such as companies focused on gene editing, genomic sequencing, genetic medicine and therapy, computational genomics and biotechnology. This fund was first introduced to the market in April 2019 and invests at least 70 percent of its assets in mid- and small-cap companies.

There are 43 holdings in this biotech fund. Its top holdings include Alnylam Pharmaceuticals (NASDAQ:ALNY) at a weight of 6.73 percent, Avidity Bioscience (NASDAQ:RNA) with a weight of 5.29 percent and Legend Biotech (NASDAQ:LEGN) at 4.52 percent.

3. Tema Obesity and Cardiometabolic ETF (NASDAQ:HRTS)

Company Profile

AUM: US$81.7 million

Launched in November 2023, the Tema Obesity and Cardiometabolic ETF tracks biotech stocks with a focus on diabetes, obesity and cardiovascular diseases. The fund was renamed on March 25; previously it was known as the Tema Cardiovascular and Metabolic ETF. More than three-quarters of its holdings are based in the US.

There are 46 holdings in this biotechnology fund, with about a 50/50 split between small- to mid-cap stocks and large-cap companies. Its top holdings include Alnylam Pharmaceuticals, Amgen at 5.65 percent and Eli Lilly and Company (NYSE:LLY) at 5.56 percent.

4. Tema Oncology ETF (NASDAQ:CANC)

Company Profile

AUM: US$47.94 million

The Tema Oncology ETF provides exposure to biotech companies operating in the oncology industry. It includes companies developing a range of cancer treatments, including CAR-T cell therapies and bispecific antibodies.

Launched in August 2023, this biotechnology fund has 49 holdings, with about 46 percent being small- to mid-cap stocks and 4.6 percent being micro stocks. Among its top holdings are Regeneron Pharmaceuticals at a weight of 6.1 percent, AstraZeneca (NASDAQ:AZN) at 5.87 percent and argenx SE (NASDAQ:ARGX) at 4.55 percent.

5. Virtus LifeSci Biotech Products ETF (ARCA:BBP)

Company Profile

AUM: US$20.88 million

The Virtus LifeSci Biotech Products ETF tracks the performance of US-listed biotech stocks with at least one drug therapy approved by the US Food and Drug Administration or in the late stages of clinical development.

Over 70 percent of its holdings are in small- and mid-cap stocks and over 85 percent of its holdings are US companies. Its top holdings are Alnylam Pharmaceuticals at 2.64 percent, Mirum Pharmaceuticals (NASDAQ:MIRM) at 2.35 percent and ADMA Biologics (NASDAQ:ADMA) at 2.32 percent.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

previous post
Top 10 Graphite-producing Countries (Updated 2024)
next post
Daydream-2 Operations Update

You may also like

Silver47 Closes First Tranche of Non-brokered Private Placement

March 6, 2025

Meta, Microsoft Shares Down Despite Beating Expectations in...

November 2, 2024

Transformational Acquisition of the High-Grade Elizabeth Hill Silver...

March 24, 2025

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual...

November 30, 2024

Green River Gold Corp. Announces an Expansion into...

January 25, 2025

Nickel Price 2024 Year-End Review

January 8, 2025

Chris Taylor Sets Sights on Gold, Antimony in...

February 8, 2025

Crypto Market Recap: UAE Readies Digital Dirham CBDC,...

March 29, 2025

AMERICAN SALARS LITHIUM PORTFOLIO HEDGED AMID TRUMP TARIFF...

March 12, 2025

Doug Casey: Gold to Go Much Higher; “Very...

November 24, 2024

Recent Posts

  • Kennedy and Milei double down on WHO exit after meeting in Buenos Aires: ‘Free from totalitarian control’
  • Trump claims Canada ‘considering’ offer of free Golden Dome in exchange for becoming 51st state
  • ‘Intensely loyal’ Jill Biden aide despised by White House staffers, new book claims
  • Defense Department workers no longer required to submit DOGE’s weekly production reports
  • SEN. RAND PAUL: Kennedy is confronting ‘corrupt’ health agencies to Make America Healthy Again

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (744)
    • Investing (2,191)
    • Politics (2,709)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.